Literature DB >> 10830246

Mycophenolate mofetil decreases endothelial prostaglandin E2 in response to allogeneic T cells or cytokines.

R A Blaheta1, K Nelson, E Oppermann, K Leckel, S Harder, J Cinatl, S Weber, M Shipkova, A Encke, B H Markus.   

Abstract

BACKGROUND: Prostaglandin E2 (PGE2) is a powerful endogenous immune suppressant and interferes with various T-cell functions. However, it is not known in detail whether immunosuppressive drugs influence the PGE2-driven immune response in transplant patients. Therefore, we investigated the effect of several immunosuppressive compounds, in particular the novel drug mycophenolate mofetil (MMF), on endothelial PGE2 release.
METHODS: Endothelial cells (HUVEC) were activated by either allogeneic CD4+ or CD8+ T cells, or by the cytokines interleukin-1 or gamma-interferon. Using an enzyme-linked immunosorbent assay, we analyzed PGE2 release of the activated HWEC in the presence of MMF, cyclosporine, or tacrolimus. As verapamil and mibefradil also possess immunosuppressive properties, they were included in the study as well.
RESULTS: Activation of HUVEC with interleukin-1 or T cells resulted in a drastic accumulation of PGE2 in the supernatant. Cyclosporine or tacrolimus had no effect on PGE2 release. However, Ca2+ channel blockers, when applied at higher dosages, caused a significant increase in PGE2. Interestingly, MMF strongly diminished the PGE2 level in the cell culture supernatant in a concentration-dependent manner.
CONCLUSION: The results demonstrate an inhibitory effect of MMF on PGE2 production, which may lower the benefits of the PGE2-triggered immune response after organ transplantation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10830246     DOI: 10.1097/00007890-200005150-00044

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  3 in total

1.  Binding of gastrointestinal tumor cells to endothelial E- and P-selectin adhesion receptors leads to transient down-regulation of sLeX ligands in vitro.

Authors:  Horst Schuldes; Daniel Schleicher; Gottfried Mayer; Bernd H Markus; Jindrich Cinatl; Roman A Blaheta
Journal:  Int J Colorectal Dis       Date:  2003-02-01       Impact factor: 2.571

2.  The Ca2+ Channel Blocker Verapamil Inhibits the In Vitro Activation and Function of T Lymphocytes: A 2022 Reappraisal.

Authors:  José Ignacio Veytia-Bucheli; Den Alejandro Alvarado-Velázquez; Lourival Domingos Possani; Roberto González-Amaro; Yvonne Rosenstein
Journal:  Pharmaceutics       Date:  2022-07-15       Impact factor: 6.525

3.  Recalcitrant lymphocytoma cutis successfully treated with mycophenolate mofetil.

Authors:  Farhan Mahmood; Iris Yh Teo; Mark G Kirchhof
Journal:  SAGE Open Med Case Rep       Date:  2021-06-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.